Pregled bibliografske jedinice broj: 401232
Impact of aminoglycoside cycling in six tertiary intensive care units: prospective longitudinal interventional study
Impact of aminoglycoside cycling in six tertiary intensive care units: prospective longitudinal interventional study // Croatian medical journal, 49 (2008), 2; 207-214 doi:10.3325/cmj.2008.2.207 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 401232 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Impact of aminoglycoside cycling in six tertiary intensive care units: prospective longitudinal interventional study
Autori
Francetić, Igor ; Kalenić, Smilja ; Huić, Mirjana ; Merčep, Iveta ; Makar-Aušperger, Ksenija ; Likić, Robert ; Erdeljić, Viktorija ; Tripković, Vesna ; Šimić, Petra
Izvornik
Croatian medical journal (0353-9504) 49
(2008), 2;
207-214
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
aminoglycoside; cycling; tertiary intensive care units; longitudinal interventional study
Sažetak
To determine the effect of aminoglycoside cycling in six tertiary intensive care units (ICU) on the rates of sepsis, aminoglycoside resistance patterns, antibiotic consumption, and costs. This was a prospective longitudinal interventional study that measured the effect of change from first-line gentamicin usage (February 2002-February 2003) to amikacin usage (February 2003-February 2004) on the aminoglycoside resistance patterns, number of patients with gram-negative bacteremia, consumption of antibiotics, and the cost of antimicrobial drugs in 6 tertiary care ICUs in Zagreb, Croatia. The change from first-line gentamicin to amikacin usage led to a decrease in the overall gentamicin resistance of gram-negative bacteria (GNB) from 42% to 26% (P<0.001 ; z-test of proportions) and netilmicin resistance from 33% to 20% (P<0.001), but amikacin resistance did not change significantly (P=0.462), except for Acinetobacter baumanni (P=0.014). Sepsis rate in ICUs was reduced from 3.6% to 2.2% (P<0.001 ; chi(2) test), with a decline in the number of nosocomial bloodstream infections from 55/100 patient-days to 26/100 patient-days (P=0.001, chi(2) test). Furthermore, amikacin use led to a 16% decrease in the overall antibiotic consumption and 0.1 euro/patient/d cost reduction. Exclusive use of amikacin significantly reduced the resistance of GNB isolates to gentamicin and netilmicin, the number of GNB nosocomial bacteremias, and the cost of total antibiotic usage in ICUs
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
108-1080114-0016 - Modifikacija antimikrobne terapije i rezistencija patogenih mikroorganizama (Francetić, Igor, MZOS ) ( CroRIS)
108-1080114-0017 - Genotipovi i činitelji virulencije uzročnika bolničkih infekcija (Budimir, Ana, MZOS ) ( CroRIS)
Ustanove:
Medicinski fakultet, Zagreb
Profili:
Mirjana Huić
(autor)
Igor Francetić
(autor)
Petra Šimić
(autor)
Vesna Tripković
(autor)
Smilja Kalenić
(autor)
Robert Likić
(autor)
Poveznice na cjeloviti tekst rada:
Pristup cjelovitom tekstu rada doi
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
Uključenost u ostale bibliografske baze podataka::
- EMBASE (Excerpta Medica)
- MEDLINE